The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025.The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Novo Nordisk, a landmark decision that health experts say could potentially open up treatment access to more patients.The approval also gives Novo Nordisk a head start over chief rival Eli Lilly, which is currently the dominant player in the market and is ra ...